The synergistic potential between Piezo1 inhibition and integrin‐targeted agents could address tumor microenvironment‐driven resistance mechanisms, particularly in malignancies where ECM stiffness and mechanosensitive pathways drive progression [54]. This evidence concerns the gene PIEZO1 and neoplasm.